| Psoriasis |
1 |
0.95 |
| Biologic Therapy |
0 |
0.73 |
| Interleukin |
0 |
0.5 |
| Grant |
0 |
0.38 |
| Intravenous |
0 |
0.38 |
| Pustular Psoriasis |
0 |
0.38 |
| Otolaryngology |
0 |
0.36 |
| Food and Drug Administration (FDA) |
0 |
0.25 |
| Receptors |
0 |
0.25 |
| Upper Respiratory Tract Infection |
0 |
0.18 |
| Cytokines |
0 |
0.13 |
| Drug Reaction |
0 |
0.13 |
| Eosinophilia |
0 |
0.13 |
| Europe |
0 |
0.13 |
| Folliculitis |
0 |
0.13 |
| Monoclonal Antibody |
0 |
0.13 |
| Pathogenesis |
0 |
0.13 |
| Pennsylvania |
0 |
0.13 |
| Phototherapy |
0 |
0.13 |
| Respiratory Tract |
0 |
0.13 |
| Skin Lesion |
0 |
0.13 |
| Influenza |
0 |
0.12 |
| Otitis Externa |
0 |
0.12 |
| Sepsis |
0 |
0.12 |
| Skin and Soft Tissue Infection |
0 |
0.12 |
| Urinary Tract Infection |
0 |
0.12 |